The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended on Thursday 11 November that two monoclonal antibody-based medicines, Ronapreve and Regkirona, be authorised to treat Sars-CoV-2.
The committee recommended authorising Ronapreve for the treatment of the disease in adults and adolescents, aged 12 years and over and weighing at least 40 kilogrammes, who do not require supplemental oxygen and who are at risk of developing severe...